Chromadex Corp (NASDAQ:CDXC) Expected to Post Quarterly Sales of $10.80 Million
Brokerages expect Chromadex Corp (NASDAQ:CDXC) to report $10.80 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Chromadex’s earnings. The lowest sales estimate is $10.61 million and the highest is $11.00 million. Chromadex reported sales of $7.80 million during the same quarter last year, which would suggest a positive year over year growth rate of 38.5%. The business is expected to report its next earnings report on Thursday, August 8th.
On average, analysts expect that Chromadex will report full year sales of $47.13 million for the current fiscal year, with estimates ranging from $45.22 million to $49.05 million. For the next year, analysts forecast that the firm will post sales of $83.71 million, with estimates ranging from $67.42 million to $100.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for Chromadex.
Chromadex (NASDAQ:CDXC) last announced its earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.04). Chromadex had a negative net margin of 94.78% and a negative return on equity of 108.84%. The company had revenue of $10.05 million during the quarter, compared to analyst estimates of $9.80 million.
Shares of NASDAQ CDXC traded down $0.06 during trading on Friday, hitting $4.41. The company had a trading volume of 172,857 shares, compared to its average volume of 367,462. The firm’s fifty day simple moving average is $4.21. Chromadex has a fifty-two week low of $2.79 and a fifty-two week high of $5.00. The firm has a market capitalization of $248.18 million, a price-to-earnings ratio of -7.23 and a beta of 1.26. The company has a quick ratio of 1.68, a current ratio of 2.24 and a debt-to-equity ratio of 0.07.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Tieton Capital Management LLC lifted its stake in shares of Chromadex by 15.1% in the first quarter. Tieton Capital Management LLC now owns 1,257,890 shares of the company’s stock worth $5,271,000 after buying an additional 165,425 shares in the last quarter. Granite Investment Partners LLC lifted its stake in shares of Chromadex by 87.7% in the first quarter. Granite Investment Partners LLC now owns 167,689 shares of the company’s stock worth $702,000 after buying an additional 78,373 shares in the last quarter. Miracle Mile Advisors LLC purchased a new position in shares of Chromadex in the first quarter worth about $272,000. Bank of New York Mellon Corp lifted its stake in shares of Chromadex by 23.4% in the fourth quarter. Bank of New York Mellon Corp now owns 128,810 shares of the company’s stock worth $442,000 after buying an additional 24,408 shares in the last quarter. Finally, Spark Investment Management LLC purchased a new position in shares of Chromadex in the first quarter worth about $78,000. Institutional investors and hedge funds own 18.11% of the company’s stock.
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.
Featured Story: What is the Rule of 72?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.